Cocrystal Pharma (COCP) Competitors $1.41 0.00 (0.00%) As of 01:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock COCP vs. BDRX, STRO, VHAQ, MGX, QNCX, GANX, TNYA, ACHL, VOR, and BYSIShould you be buying Cocrystal Pharma stock or one of its competitors? The main competitors of Cocrystal Pharma include Biodexa Pharmaceuticals (BDRX), Sutro Biopharma (STRO), Viveon Health Acquisition (VHAQ), Metagenomi (MGX), Quince Therapeutics (QNCX), Gain Therapeutics (GANX), Tenaya Therapeutics (TNYA), Achilles Therapeutics (ACHL), Vor Biopharma (VOR), and BeyondSpring (BYSI). These companies are all part of the "pharmaceutical products" industry. Cocrystal Pharma vs. Biodexa Pharmaceuticals Sutro Biopharma Viveon Health Acquisition Metagenomi Quince Therapeutics Gain Therapeutics Tenaya Therapeutics Achilles Therapeutics Vor Biopharma BeyondSpring Cocrystal Pharma (NASDAQ:COCP) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their community ranking, risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends. Do insiders & institutionals believe in COCP or BDRX? 6.7% of Cocrystal Pharma shares are held by institutional investors. Comparatively, 17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. 25.6% of Cocrystal Pharma shares are held by company insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media favor COCP or BDRX? In the previous week, Cocrystal Pharma had 9 more articles in the media than Biodexa Pharmaceuticals. MarketBeat recorded 9 mentions for Cocrystal Pharma and 0 mentions for Biodexa Pharmaceuticals. Cocrystal Pharma's average media sentiment score of 1.05 beat Biodexa Pharmaceuticals' score of 0.00 indicating that Cocrystal Pharma is being referred to more favorably in the media. Company Overall Sentiment Cocrystal Pharma Positive Biodexa Pharmaceuticals Neutral Does the MarketBeat Community favor COCP or BDRX? Cocrystal Pharma received 23 more outperform votes than Biodexa Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Biodexa Pharmaceuticals an outperform vote while only 77.42% of users gave Cocrystal Pharma an outperform vote. CompanyUnderperformOutperformCocrystal PharmaOutperform Votes2477.42% Underperform Votes722.58% Biodexa PharmaceuticalsOutperform Votes1100.00% Underperform VotesNo Votes Which has stronger valuation & earnings, COCP or BDRX? Biodexa Pharmaceuticals has higher revenue and earnings than Cocrystal Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCocrystal PharmaN/AN/A-$17.98M-$1.85-0.76Biodexa Pharmaceuticals$83K749.81-$7.66MN/AN/A Do analysts recommend COCP or BDRX? Cocrystal Pharma currently has a consensus target price of $7.00, indicating a potential upside of 396.45%. Given Cocrystal Pharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe Cocrystal Pharma is more favorable than Biodexa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cocrystal Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Biodexa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is COCP or BDRX more profitable? Biodexa Pharmaceuticals' return on equity of 0.00% beat Cocrystal Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Cocrystal PharmaN/A -94.62% -78.24% Biodexa Pharmaceuticals N/A N/A N/A Which has more risk and volatility, COCP or BDRX? Cocrystal Pharma has a beta of 2.35, indicating that its share price is 135% more volatile than the S&P 500. Comparatively, Biodexa Pharmaceuticals has a beta of 1.7, indicating that its share price is 70% more volatile than the S&P 500. SummaryCocrystal Pharma beats Biodexa Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Remove Ads Get Cocrystal Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for COCP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COCP vs. The Competition Export to ExcelMetricCocrystal PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.35M$6.44B$5.33B$7.16BDividend YieldN/A2.85%4.87%4.06%P/E Ratio-0.766.8322.9417.50Price / SalesN/A190.01357.9385.03Price / CashN/A65.6738.1634.64Price / Book0.545.656.263.82Net Income-$17.98M$142.17M$3.21B$247.19M7 Day Performance-4.73%-11.22%-7.86%-7.19%1 Month Performance-19.66%-14.31%-2.83%-9.97%1 Year Performance-4.08%-18.16%3.74%-7.26% Cocrystal Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COCPCocrystal Pharma3.1313 of 5 stars$1.41flat$7.00+396.5%-2.8%$14.35MN/A-0.7610Analyst RevisionNews CoveragePositive NewsGap UpBDRXBiodexa Pharmaceuticals0.1388 of 5 stars$1.75-1.1%N/AN/A$63.95M$83,000.000.0020Gap UpSTROSutro Biopharma3.8038 of 5 stars$0.77+0.4%$6.63+760.1%-88.4%$63.52M$62.04M-0.48240Gap UpVHAQViveon Health AcquisitionN/A$11.00flatN/AN/A$62.26MN/A0.002High Trading VolumeMGXMetagenomi1.6564 of 5 stars$1.65+0.6%$14.40+772.7%-88.0%$61.68M$52.30M-0.63236Analyst ForecastQNCXQuince Therapeutics2.2185 of 5 stars$1.40+1.4%$9.60+585.7%+20.0%$61.60MN/A-1.1360GANXGain Therapeutics3.1033 of 5 stars$2.32-0.9%$8.20+253.4%-55.1%$61.54M$50,000.00-2.1120Analyst RevisionPositive NewsTNYATenaya Therapeutics3.8481 of 5 stars$0.70+10.0%$6.25+792.9%-89.1%$61.31MN/A-0.49110Analyst RevisionGap DownACHLAchilles Therapeutics2.8211 of 5 stars$1.48flat$4.00+170.3%N/A$60.83MN/A-0.90250VORVor Biopharma1.7824 of 5 stars$0.88+1.7%$8.86+901.5%-71.9%$60.74MN/A-0.54140BYSIBeyondSpringN/A$1.55-3.1%N/A-53.4%$60.50M$1.88M0.0080Gap Down Remove Ads Related Companies and Tools Related Companies BDRX Competitors STRO Competitors VHAQ Competitors MGX Competitors QNCX Competitors GANX Competitors TNYA Competitors ACHL Competitors VOR Competitors BYSI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COCP) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredRUTHLESS Musk Move >> coming June 1?Elon Musk has made headlines with everything from mass layoffs to political drama — but his next move could sh...Paradigm Press | SponsoredNearly $3 Trillion Gone…Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow you could profit from Elon’s latest AI breakthroughEvery single one of Elon's projects minted an entire new class of millionaires. And xAI could be next in li...Behind the Markets | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredTrump’s betrayal exposed Fair warning: this will not make for easy viewing. Especially if you voted for Trump, put your faith in hi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cocrystal Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cocrystal Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
